Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease
- PMID: 32145376
- DOI: 10.1016/j.nbd.2020.104831
Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease
Abstract
Objectives: Cholinergic dysfunction plays a prominent role in cognitive impairment in Parkinson's disease (PD). The aim of this study was to assess the relationship of baseline and longitudinal basal forebrain atrophy with cognitive decline and dementia in PD.
Methods: We included 106 non-demented PD patients, 19 PD dementia (PDD) patients and 42 controls with longitudinal structural MRI and cognitive testing. After 4.2 ± 1.8 years, 20 non-demented PD patients were diagnosed with dementia (PD-dementia converters), whereas the rest of PD patients remained non-demented (stable-PD). We compared MRI volumes of the medial septum/diagonal band (Ch1/Ch2) and nucleus basalis of Meynert (Ch4) between groups. Cox regression analyses were applied to test whether Ch1/Ch2 or Ch4 atrophy could predict future dementia and linear mixed models assessed their association with cognitive decline.
Results: Compared to controls, we found reduced Ch4 baseline volumes in PD-dementia converters (p = .003) and those who already had PDD (p < .001) but not in stable-PD. Over time, there was a greater loss in Ch1/Ch2 volumes in PD-dementia converters and PDD compared to the other groups (p = .004). Baseline and longitudinal Ch4 volumes were associated with cognition (p < .002) and longitudinal Ch4 atrophy predicted future dementia (p = .009).
Conclusions: Atrophy of Ch4 precedes and predicts future dementia in PD and is followed by changes in Ch1/Ch2, reflecting a posterior-anterior pattern of basal forebrain atrophy. This pattern could be used to track the spread of cholinergic degeneration and identify patients at risk of developing dementia.
Keywords: Basal forebrain; Cognitive decline; Dementia; Longitudinal MRI; Parkinson's disease.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. The rest of authors have no conflicts of interest.
Similar articles
-
In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.Brain. 2018 Jan 1;141(1):165-176. doi: 10.1093/brain/awx310. Brain. 2018. PMID: 29228203 Free PMC article.
-
Quantitative EEG and cholinergic basal forebrain atrophy in Parkinson's disease and mild cognitive impairment.Neurobiol Aging. 2021 Oct;106:37-44. doi: 10.1016/j.neurobiolaging.2021.05.023. Epub 2021 Jun 5. Neurobiol Aging. 2021. PMID: 34233212
-
Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in "cognitive status" converters?Hum Brain Mapp. 2020 Apr 15;41(6):1416-1434. doi: 10.1002/hbm.24884. Epub 2019 Dec 2. Hum Brain Mapp. 2020. PMID: 31789477 Free PMC article.
-
MRI and cognitive impairment in Parkinson's disease.Mov Disord. 2009;24 Suppl 2:S748-53. doi: 10.1002/mds.22670. Mov Disord. 2009. PMID: 19877242 Review.
-
Nucleus basalis of Meynert degeneration predicts cognitive impairment in Parkinson's disease.Handb Clin Neurol. 2021;179:189-205. doi: 10.1016/B978-0-12-819975-6.00010-8. Handb Clin Neurol. 2021. PMID: 34225962 Review.
Cited by
-
Neuronal PAS domain 1 identifies a major subpopulation of wakefulness-promoting GABAergic neurons in the basal forebrain.Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2321410121. doi: 10.1073/pnas.2321410121. Epub 2024 May 15. Proc Natl Acad Sci U S A. 2024. PMID: 38748575
-
Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes.Brain Commun. 2024 Apr 16;6(3):fcae130. doi: 10.1093/braincomms/fcae130. eCollection 2024. Brain Commun. 2024. PMID: 38715714 Free PMC article.
-
EEG Frequency Correlates with α2-Receptor Density in Parkinson's Disease.Biomolecules. 2024 Feb 10;14(2):209. doi: 10.3390/biom14020209. Biomolecules. 2024. PMID: 38397446 Free PMC article.
-
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease.Brain. 2024 Jun 3;147(6):1937-1952. doi: 10.1093/brain/awae026. Brain. 2024. PMID: 38279949 Free PMC article. Review.
-
Pathobiology of Cognitive Impairment in Parkinson Disease: Challenges and Outlooks.Int J Mol Sci. 2023 Dec 29;25(1):498. doi: 10.3390/ijms25010498. Int J Mol Sci. 2023. PMID: 38203667 Free PMC article. Review.